Covaxin has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial, says Bharat Biotech.

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with Indian Council of Medical Research, it said.

More details awaited.   -- ANI